Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

2013 ASCO Annual Meeting

30 May - 3 Jun 2013

McCormick Place, Chicago, United States of America

Role of microenvironment and stroma in cancer therapy

Dr Stephen Ansell - Mayo Clinic, Rochester, USA

Role of microenvironment and stroma in cancer therapy ( Dr Stephen Ansell - Mayo Clinic, Rochester, USA )

Adding bevacizumab to standard first-line chemoradiation for glioblastoma gives no survival benefit

Prof Mark Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA

Adding bevacizumab to standard first-line chemoradiation for glioblastoma gives no survival benefit ( Prof Mark Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA )

Science behind phase I clinical trials: targeting tumour cell development pathways

Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA

Science behind phase I clinical trials: targeting tumour cell development pathways ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )

ASCO 2013 highlights

Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA

ASCO 2013 highlights ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )

Crizotinib superior to chemo for advanced ALK positive NSCLC

Dr Suresh S. Ramalingam - Emory University, Atlanta, USA

Crizotinib superior to chemo for advanced ALK positive NSCLC ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )

Next generation of anti-cancer agents: data from ASCO 2013

Dr Sarah Blagden - Imperial College, London, UK

Next generation of anti-cancer agents: data from ASCO 2013 ( Dr Sarah Blagden - Imperial College, London, UK )

Phase I study measures effect of ipilimumab and nivolumab combination in melanoma patients

Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Phase I study measures effect of ipilimumab and nivolumab combination in melanoma patients ( Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )

Axillary radiotherapy provides alternative to invasive early stage breast cancer surgery

Dr Emiel J. Rutgers - Netherlands Cancer Institute, Amsterdam

Axillary radiotherapy provides alternative to invasive early stage breast cancer surgery ( Dr Emiel J. Rutgers - Netherlands Cancer Institute, Amsterdam )

Comment on progression free survival in lung cancer patients and the GALAXY-1 trial

Dr Marjorie G. Zauderer - Memorial Sloan-Kettering Cancer Center, New York, USA

Comment on progression free survival in lung cancer patients and the GALAXY-1 trial ( Dr Marjorie G. Zauderer - Memorial Sloan-Kettering Cancer Center, New York, USA )

Paclitaxel dosing equally effective in preventing breast cancer progression

Dr Andrew Seidman - Memorial Sloan-Kettering Cancer Center, New York, USA

Paclitaxel dosing equally effective in preventing breast cancer progression ( Dr Andrew Seidman - Memorial Sloan-Kettering Cancer Center, New York, USA )

Biennial cervical cancer screening with vinegar reduces mortality

Dr Surendra Srinivas Shastri - Tata Memorial Hospital Mumbai, India

Biennial cervical cancer screening with vinegar reduces mortality ( Dr Surendra Srinivas Shastri - Tata Memorial Hospital Mumbai, India )

Paclitaxel chemotherapy schedules equally effective for early-stage breast cancer

Dr G. Thomas Budd - Cleveland Clinic, Cleveland, USA

Paclitaxel chemotherapy schedules equally effective for early-stage breast cancer ( Dr G. Thomas Budd - Cleveland Clinic, Cleveland, USA )

Ganetespib inhibits Hsp90 with docetaxel for advanced lung cancer

Dr Suresh S. Ramalingam - Emory University, Atlanta, USA

Ganetespib inhibits Hsp90 with docetaxel for advanced lung cancer ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )

Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )

Nivolumab blocking PD1 in lung cancer and melanoma

Dr Suzanne Topalian - Johns Hopkins Medical Center, Baltimore, USA

Nivolumab blocking PD1 in lung cancer and melanoma ( Dr Suzanne Topalian - Johns Hopkins Medical Center, Baltimore, USA )

Crizotinib and molecular testing in advanced non small cell lung cancer

Dr Fred Hirsch - University of Colorado, Denver, USA

Crizotinib and molecular testing in advanced non small cell lung cancer ( Dr Fred Hirsch - University of Colorado, Denver, USA )

Nintedanib in combination with standard second line therapy in lung cancer

Dr Martin Reck - Hospital Grosshansdorf, Wohrendamm, Germany

Nintedanib in combination with standard second line therapy in lung cancer ( Dr Martin Reck - Hospital Grosshansdorf, Wohrendamm, Germany )

The problem of unnecessary treatment of prostate cancer

Dr Rosalind Eeles - Royal Marsden Hospital, London, UK

The problem of unnecessary treatment of prostate cancer ( Dr Rosalind Eeles - Royal Marsden Hospital, London, UK )

Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer

Dr Suresh S. Ramalingam - Emory University, Atlanta, USA

Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )

One in five african american women with breast cancer carry inherited mutations

Dr Jane E. Churpek - University of Chicago, USA

One in five african american women with breast cancer carry inherited mutations ( Dr Jane E. Churpek - University of Chicago, USA )

Axillary radiotherapy provides alternative to invasive early stage breast cancer surgery

Dr Emiel J. Rutgers - Netherlands Cancer Institute, Amsterdam

Axillary radiotherapy provides alternative to invasive early stage breast cancer surgery ( Dr Emiel J. Rutgers - Netherlands Cancer Institute, Amsterdam )

Paclitaxel chemotherapy schedules are equally effective for early-stage breast cancer

Dr G. Thomas Budd - MD Cleveland Clinic, USA

Paclitaxel chemotherapy schedules are equally effective for early-stage breast cancer ( Dr G. Thomas Budd - MD Cleveland Clinic, USA )

Surveys reveal shortages of common cancer drugs are ongoing

Dr Keerthi Gogineni - University of Pennsylvania, Philadelphia, USA

Surveys reveal shortages of common cancer drugs are ongoing ( Dr Keerthi Gogineni - University of Pennsylvania, Philadelphia, USA )

Selumetinib, the first effective drug for advanced melanoma of the eye

Dr Richard Carvajal - Memorial Sloan Kettering Cancer Center, New York, USA

Selumetinib, the first effective drug for advanced melanoma of the eye ( Dr Richard Carvajal - Memorial Sloan Kettering Cancer Center, New York, USA )

Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer

Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA

Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer ( Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA )

Extended use of tamoxifen reduces breast cancer recurrence and death

Prof Richard Gray - University of Oxford, Oxford, United Kingdom

Extended use of tamoxifen reduces breast cancer recurrence and death ( Prof Richard Gray - University of Oxford, Oxford, United Kingdom )

Ipilimumab and BRAF inhibitors for advanced melanoma

Dr Lynn Schuchter - University of Pennsylvania, USA

Ipilimumab and BRAF inhibitors for advanced melanoma ( Dr Lynn Schuchter - University of Pennsylvania, USA )

Effect of metformin on cancer risk and mortality

Dr Sara Gandini - European Institute of Oncology (IEO), Milan, Italy

Effect of metformin on cancer risk and mortality ( Dr Sara Gandini - European Institute of Oncology (IEO), Milan, Italy )

PDL1 inhibitors in melanoma

Dr Roy Herbst - Yale Cancer Center, New Haven, USA

PDL1 inhibitors in melanoma ( Dr Roy Herbst - Yale Cancer Center, New Haven, USA )

Ten years of tamoxifen superior to five in reducing breast cancer recurrence and death

Dr Richard G. Gray - University of Oxford, UK

Ten years of tamoxifen superior to five in reducing breast cancer recurrence and death ( Dr Richard G. Gray - University of Oxford, UK )

Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer

Dr Marcia Brose - Abramson Cancer Center, University of Pennsylvania, USA

Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer ( Dr Marcia Brose - Abramson Cancer Center, University of Pennsylvania, USA )

No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma

Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA

No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma ( Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA )

Bevacizumab extends survival for relapsed and advanced cervical cancer

Dr Krishnansu Sujata Tewari - University of California Irvine Medical Center, USA

Bevacizumab extends survival for relapsed and advanced cervical cancer ( Dr Krishnansu Sujata Tewari - University of California Irvine Medical Center, USA )

Biennial cervical cancer screening with vinegar reduces mortality

Dr Surendra Srinivas Shastri - Tata Memorial Hospital Mumbai, India

Biennial cervical cancer screening with vinegar reduces mortality ( Dr Surendra Srinivas Shastri - Tata Memorial Hospital Mumbai, India )

Comment on drug developments in advanced melanoma

Dr Roy Herbst - Yale Cancer Center, New Haven, USA

Comment on drug developments in advanced melanoma ( Dr Roy Herbst - Yale Cancer Center, New Haven, USA )

Lapatinib in combination with chemotherapy in breast cancer

Dr J. Randolph Hecht - UCLA Medical Center, Santa Monica, USA

Lapatinib in combination with chemotherapy in breast cancer ( Dr J. Randolph Hecht - UCLA Medical Center, Santa Monica, USA )

Brentuximab vedotin in the frontline setting

Dr Stephen Ansell - Mayo Clinic, Rochester, USA

Brentuximab vedotin in the frontline setting ( Dr Stephen Ansell - Mayo Clinic, Rochester, USA )

Comment on biennial visual inspection with acetic acid (VIA), or vinegar

Prof Krishnansu Sujata Tewari - University of California Irvine, Orange, USA

Comment on biennial visual inspection with acetic acid (VIA), or vinegar ( Prof Krishnansu Sujata Tewari - University of California Irvine, Orange, USA )

Effects of The Cancer Genome Atlas

Dr Matthew Ellis - Washington University in St Louis, USA

Effects of The Cancer Genome Atlas ( Dr Matthew Ellis - Washington University in St Louis, USA )

AMAROS trial: radiotherapy versus lymph node dissection in breast cancer

Dr Robert Mansel - Cardiff University, UK

AMAROS trial: radiotherapy versus lymph node dissection in breast cancer ( Dr Robert Mansel - Cardiff University, UK )

Cetuximab superior to bevacizumab for advanced colorectal cancer

Dr Volke Heinemann - University of Munich Munich, Germany

Cetuximab superior to bevacizumab for advanced colorectal cancer ( Dr Volke Heinemann - University of Munich Munich, Germany )

Improving outcomes of childhood neuroblastoma

Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia, USA

Improving outcomes of childhood neuroblastoma ( Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia, USA )

Nivolumab produces long-lasting responses in patients with stage IV melanoma

Dr Mario Sznol - Yale Cancer Center, New Haven, USA

Nivolumab produces long-lasting responses in patients with stage IV melanoma ( Dr Mario Sznol - Yale Cancer Center, New Haven, USA )

Delayed relapse of advanced ovarian cancer when treating with pazopanib

Dr Andreas du Bois - Kliniken Essen Mitte, Essen, Germany

Delayed relapse of advanced ovarian cancer when treating with pazopanib ( Dr Andreas du Bois - Kliniken Essen Mitte, Essen, Germany )

Cetuximab superior to bevacizumab for advanced colorectal cancer

Dr Volker Heinemann - University of Munich, Germany

Cetuximab superior to bevacizumab for advanced colorectal cancer ( Dr Volker Heinemann - University of Munich, Germany )

Spouses of patients with HPV-positive oropharyngeal cancer do not have increased oral HPV infections

Dr Gypsyamber D’Souza - Johns Hopkins Bloomberg School of Public Health, Baltimore, USA

Spouses of patients with HPV-positive oropharyngeal cancer do not have increased oral HPV infections ( Dr Gypsyamber D’Souza - Johns Hopkins Bloomberg School of Public Health, Baltimore, USA )

New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye

Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA

New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye ( Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA )

Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma

Dr Mario Sznol - Yale Cancer Center New Haven, USA

Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma ( Dr Mario Sznol - Yale Cancer Center New Haven, USA )

Maintenance therapy with multi-targeted drug pazopanib delays relapse of advanced ovarian cancer

Dr Andreas du Bois - Kliniken Essen Mitte, Germany

Maintenance therapy with multi-targeted drug pazopanib delays relapse of advanced ovarian cancer ( Dr Andreas du Bois - Kliniken Essen Mitte, Germany )

Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer